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Introduction
Multiple Sclerosis (MS) is a complex disease of the central 
nervous system (CNS) in which a diverse interplay of 
immunological factors contribute to a characteristically 
variable pathology, phenotypic presentation, disease course 
and prognosis.1,2 With the possible exception of magnetic 
resonance imaging (MRI), where use in prediction of pro-
gression is not established with any degree of certainty,3 
there are currently no biomarkers for MS which reliably 
predict prognosis at disease onset or enable monitoring of 
disease progression. With the recent introduction of thera-
pies which can significantly alter the natural history of MS, 
but which may have significant risks associated with their 
use,4-6 the importance of accurate diagnosis and prediction 
of disease severity and outcome at an early stage of disease 
is becoming increasingly apparent. Identification of effec-
tive, accessible biomarkers would have significant transla-
tional benefits and an immediate and important role in the 
clinical management and treatment of patients with MS.
The exact characterisation of the immunopathology of 
MS remains an emerging field, and recent advances have 
implicated innate immune mechanisms as playing an 
important role.7,8 In addition, although no complement 
genes were among the top hits in the recent genomewide 
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association study in MS, multiple immunologically rele-
vant genes, several of which interact with and influence 
propagation of the complement system (e.g. IL2 and its 
receptor; IL7 and its receptor) were identified. Complement, 
a key component of the innate immune system, has an 
established role in the pathogenesis of MS (for review see 
Ingram et al.9); however, despite evidence from pathologi-
cal,10,11 functional12,13 and animal14 models, the extent and 
precise nature of complement activation in MS, and its con-
tribution to disease phenotype and long-term outcome, 
remain unclear.
Recently, we have evaluated complement regulator fac-
tor H (fH)15 and an activation fragment of C4, C4a,16 in MS 
as potential biomarkers for MS disease course. Building on 
evidence from these initial studies, we set out to examine 
the role and extent of activation and regulation of comple-
ment in a comprehensively phenotyped population of 
patients with MS. Representative proteins from all comple-
ment activitation pathways (classical, alternative and termi-
nal) were strategically chosen to provide a comprehensive 
picture of complement components, activation products 
and regulators. Plasma complement profiles were estab-
lished for different disease courses and evaluated as predic-
tive models of disease state.
Methods
Subjects
Plasma samples were obtained prospectively between 2006 
and 2010, from 176 patients with clinically definite MS,17 
including 37 patients with stable relapsing–remitting MS 
(S-RRMS) with no clinically evident relapse for at least 12 
months, 68 with acute relapsing–remitting MS (A-RRMS) 
sampled in relapse, 34 with secondary progressive MS 
(SPMS), and 37 with primary progressive MS (PPMS). 
Assays were initially performed in a pilot study with 20 
patients in each group. For components showing some vari-
ation between groups (including all components except Bb 
and clusterin), additional analysis was performed to 
increase subgroup size to between 30 and 40 patients, 
which from the pilot study gave a calculated power of 99% 
with confidence levels of 95%. Further analysis of 44 
patients serially sampled in acute relapse and at intervals 
thereafter was performed on assays showing variation in 
acute relapse (including all components except Bb, C1 
inhibitor (C1inh), clusterin and FI). The total number of 
patients analysed in each subgroup is shown in the results. 
Detailed clinical information was available on all patients 
including age, age at onset, disease duration and disability 
assessed by the Expanded Disability Status Scale (EDSS).18 
No patients were on disease-modifying treatments. Of the 
68 patients with A-RRMS, 44 remained relapse free over a 
5–7-month period and underwent serial plasma sampling at 
intervals of between 2–3 months and 5–7 months post 
relapse. No patients seen in relapse had intercurrent infec-
tions; 71.8% were treated with oral or intravenous steroids 
after plasma samples had been collected, and the reminder 
were untreated. Relapses were classified according to 
detailed anatomical and clinical characteristics; 10 patients 
had experienced brainstem or cerebellar relapses, 40 pyrim-
idal or long tract motor relapses, four optic neuritis and six 
pure long tract sensory relapses. In patients who were seri-
ally sampled, mean EDSS at relapse was 4.72 (SD 1.64); 
this improved by a mean of 1.08 points (SD 1.07) at 2–3 
months and by 1.09 points (SD 1.15) at 5–7 months follow-
ing relapse. The control group comprised 35 non-related 
subjects with no personal or family history of neurological 
disease. Demographic details of patients and controls are 
displayed in Table 1. Patients selected for this study 
included the RRMS and SPMS patients and controls used 
in the replication phase of prior work, and therefore some 
of the fH data shown for these patients have been published 
previously.15
Cerebrospinal fluid (CSF) was obtained with paired 
plasma samples from 66 patients who had been admitted 
for investigation of suspected or known MS. Of these, five 
had a clinically isolated syndrome (CIS) and 24 patients 
were subsequently found to have symptoms not related to 
demyelinating disease; these samples were used as 
Table 1. Demographic details of total multiple sclerosis population and controls.
No. Gender Age DD EDSS MSSS  
 % f Mean SD Mean SD Mean SD Mean SD
Control 35 60.00 50.57 19.54 N/A N/A N/A N/A N/A N/A
Total MS 176 68.18 44.39 12.44 11.63 10.44 4.90 2.09 6.52 2.60
S-RRMS 37 83.78 41.76 9.65 8.27 9.71 2.59 1.41 4.41 2.65
A-RRMS 68 77.94 36.28 9.05 8.47 8.09 4.56 1.53 6.64 2.53
SPMS 34 50.00 54.03 9.07 22.88 10.31 6.97 1.21 7.29 2.06
PPMS 37 51.35 53.05 11.62 10.43 8.02 5.92 1.66 7.71 1.86
DD, disease duration; EDSS, Expanded Disability Status Scale; MSSS, MS Severity Score; f, female; SD, standard deviation; S-RRMS, stable relapsing–re-
mitting MS with no relapses reported for at least 12 months; A-RRMS, acute relapsing–remitting MS sampled in relapse; SPMS, secondary progressive 
MS; PPMS, primary progressive MS.
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controls. Subsequent neurological diagnosis within the 
control group included structural cervical myelopathy, cer-
ebrovascular disease, trigeminal neuralgia, fibromyalgia, 
vestibular neuronitis and Sjogren’s syndrome. Of the 37 
patients with MS, disease subgroups consisted of 28 
patients with S-RRMS, five patients with A-RRMS in acute 
relapse and four patients with progressive disease.
Informed consent was obtained from all patients and 
ethical approval was gained from South East Wales Ethics 
committee (ref no.05/WSE03/112 and ref no. MRCE 
04/9/025).
Samples
Plasma samples were separated (2000 g/10 mins) within 3 
h of collection and stored in aliquots at -80°C until analysis. 
CSF was taken in line with published guidelines,19 atrau-
matically from vertebral body L3–5; bloody samples were 
discarded. Samples were centrifuged (2000 g/10 mins) to 
remove cells and debris within 30 min of collection before 
being aliquoted and frozen at –80°C until use.
Measurement of factor B (fB)
A sandwich enzyme-linked immunosorbent assay (ELISA) 
for quantification of fB in plasma, serum or CSF samples 
was developed in-house. Maxisorp (Nunc Life 
Technologies) plates were coated with in-house monoclo-
nal mouse anti-human fB (JC1, 100 µl, 5 mg/l) overnight at 
4°C, washed in 0.1% Tween 20 in PBS (washing buffer) 
and blocked with 200 µl 1% BSA/10 mM EDTA (blocking 
buffer) in PBS. After a single wash in washing buffer, 100 
µl of standards, plasma (diluted 1:3000 in blocking buffer) 
or CSF (diluted 1:10 in blocking buffer) samples were 
added in duplicate and incubated. Wells were washed three 
times in washing buffer and incubated with 100 µl of HRP-
labelled affinity-purified rabbit polyclonal anti-human fB 
(in-house; 1 mg/l). All incubations were stationary, 1 h, 
37°C, unless stated otherwise. Wells were washed three 
times in washing buffer and bound antibody was visualised 
with orthophenylenediamine (SIGMAFAST™ OPD). 
Development was stopped by the addition of 10% sulphuric 
acid, and absorbance at 492 nm was measured. Purified 
human fB was used as a standard for estimation of plasma 
fB. Control standards were included on each plate. 
Concentration of fB in plasma or CSF was calculated by 
reference to the appropriate calibration curve prepared 
from the standards and expressed as mg/l of plasma or CSF. 
A nonlinear regression model was used to fit standard 
curves generated by ELISA. The calculated detection limit 
of the assay was 0.006 mg/l and the working range 0.01–
0.2 mg/l. The assay performance was assessed by taking 
multiple measures from independently diluted aliquots of 
the same plasma samples, either within the same assay or in 
separate assays. The within-assay precision (coefficient of 
variation (CV) %), ranged from 6–8% with an average of 
7%. Between-assay precision ranged from 5–11% with an 
average of 9%.
Measurement of C9
A sandwich ELISA for quantification of C9 in plasma, 
serum or CSF samples was developed in-house with meth-
ods as described above. Coating antibody for C9 detection 
was used at 1 mg/l, 100 µl/well (B7 monoclonal anti-C9, 
in-house). Plasma samples were diluted 1:2000 in blocking 
buffer and CSF was diluted 1:10 in blocking buffer. HRP-
labelled monoclonal mouse anti-human C9 (MAC68, in-
house) was added to wells for detection of C9 (100 µl; 1 
mg/l). The assay was standardised using pure C9. The cal-
culated detection limit was 0.003 mg/l with a working 
range of 0.010–0.16 mg/l. The within-assay precision 
(CV%) ranged from 0–4% with an average of 3% and 
between-assay precision ranged from 0–11% with an aver-
age of 6%.
Measurement of C1s
A sandwich ELISA for quantification of C1s in plasma, 
serum or CSF samples was developed in-house with meth-
ods as described above. Coating antibody for C1s (F33, in-
house) was used at 5 mg/l, 100 µl/well. Plasma samples were 
diluted 1:2000 in blocking buffer and CSF was diluted 1:10 
in blocking buffer for both assays. For detection of C1s, goat 
polyclonal antiserum to human C1s (A302, Quidel, www.
quidel.com) was added to each well (100 µl; 1:2000), fol-
lowed by HRP-labelled polyclonal rabbit anti-goat immuno-
globulins (P0449, Dako UK Ltd, www.dako.com). The assay 
was standardised using pure C1s. The calculated detection 
limit of the assay was 0.003 mg/l with a working range of 
0.015–0.25 mg/l. The within-assay precision (CV%) ranged 
from 0–5% with an average of 4% and between-assay preci-
sion ranged from 0–12% with an average of 6%.
Measurement of fH
The assay for the detection of fH has previously been 
described in detail.15,20 Of note, many papers quote higher 
levels of serum fH; the extinction coefficients for fH stand-
ards on which our normal range is based have been 
described previously.20 The calculated detection limit of the 
assay was 0.007 mg/l and the working range 0.01–0.2 mg/l. 
The within-assay precision ranged from 4–7% with an 
average of 5% and between-assay precision ranged from 
5–10% with an average of 8%.
Measurement of factor I
A sandwich ELISA for quantification of fI in plasma, serum 
or CSF samples was developed in-house with methods as 
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described above. Coating antibody for fI detection was 
used at 5 mg/l, 100 µl/well (MBI-1 monoclonal anti-fI, in-
house). Plasma samples were diluted 1:100 in blocking 
buffer and CSF was diluted 1:5 in blocking buffer. 
Commercial polyclonal goat anti-human fI (A238, 
Complement Technology Inc, www.complementtech.com) 
was added to wells (100 µl at 1:1000 dilution), followed by 
HRP-labelled polyclonal rabbit anti-goat immunoglobulins 
(100 µl at 1:4000 dilution). The assay was standardised 
using pure fI. The calculated detection limit of the fI assay 
was 0.015 mg/l with a working range of 0.025–0.6 mg/l. 
The within-assay precision ranged from 6–8% with an 
average of 7% and between-assay precision was 10%.
Measurement of clusterin, TCC, Bb and C4a
Clusterin was quantified using a commercial assay from 
ALPCO diagnostics (44-CLUHU-E05, www.alpco.com). 
TCC was quantified using a commercial assay from Hycult 
Biotech, working range 8.2–2000 mAU (activating units)/ml 
(HK328, www.hycultbiotech.com). Activation product Bb 
was quantified using a commercial assay from Quidel (A027, 
www.quidel.com). Activation product C4a was quantified 
using a commercial assay from BD Biosciences (550947, 
www.bdbiosciences.com) as described elsewhere.16
Measurement of C3, C4, C1 inhibitor and 
C-reactive protein
C3, C4 and C1inh concentrations were measured by neph-
elometry on a Beckman BN11 nephlometer in the University 
Hospital of Wales Clinical Immunology laboratory using 
commercial standards. The assay working range for C3 was 
0.02–4.1 g/l, for C4 was 0.01–1.9 g/l and for C1inh was 
0.02–0.6 g/l. C-reactive protein (CRP) was measured by 
laser nephelometry in the University Hospital of Wales 
Clinical Immunology laboratory, with a lower detection 
limit of 0.04mg/l.
Routine CSF analysis
CSF and paired serum samples were analysed in the routine 
laboratory for IgG, albumin and oligoclonal bands (OCB). 
IgG and albumin were measured on the BN 11 nephlome-
ter, and OCBs on the Sebia Hydrasys system (400-1705 
Corporate Drive, Norcross, GA 30093; www.sebia-usa.
com) using Hydrogel 9 CSF Iso-electric focussing gels. 
Reference ranges were: serum IgG 5.2–15.5 g/l, CSF IgG 
<58 mg/l, serum albumin 35–50 g/l, CSF albumin 160–360 
mg/l, albumin/IgG index 0.3–0.8.
Statistical analyses
Data analysis was performed using SPSS version 16 (SPSS 
Inc., Chicago, IL, USA) statistical package. All data were 
normally distributed. Quantitative concentrations were 
compared between disease subgroups using either Student’s 
t-test for 2-way analysis (MS versus controls), or analysis 
of variance (ANOVA) for multiple comparisons between 
subgroups. If the ANOVA showed a statistical difference 
between subgroups a post-hoc analysis with Bonferonni 
correction for multiple comparisons was performed. 
Variables showing statistical significant difference at t-test 
were included in a logisitic regression model and odds 
ratios (ORs) with 95% confidence intervals (CIs) were cal-
culated. Objective clinical characteristics such as age, gen-
der and disease duration were added to the model and 
concordance, or the C statistic was calculated based on the 
area under Receiver operated characteristics (ROC) curve, 
to assess whether individual components or combined 
models contributed to predicting binary outcomes (a per-
fect score would be 1.0 or 100% predictability). Correlations 
were performed using Pearson’s correlation coefficient and 
then modelled using multivariate regression analysis to 
assess any dominant effect. Subgroup analysis of CSF was 
limited by number of samples and is therefore presented as 
median values and analysed using the non-parametric 
Mann–Whitney test to compare groups. Sample sizes for 
2-way analysis of CSF, comparing subgroups with normal 
and raised IgG and albumin ratios, were larger and nor-
mally distributed and therefore are presented as means and 
compared using the Student’s t-test.
Results
Plasma complement levels predict MS 
compared with a control population
Compared with healthy controls, the total MS population 
analysed showed increased mean levels of plasma C3 and 
C4, reduced levels of plasma C9, and no difference in mean 
levels of plasma proteins C1s and fB (Table 2, Figure 1). 
There was a significant increase in plasma levels of activa-
tion product C4a; however, as shown previously, this eleva-
tion was seen only in the A-RRMS group.16 No changes 
were seen in activation product Bb, and levels of TCC were 
undetectable in the plasma with a lower assay detection 
limit of 8.2 mAU/ml (Table 3). Complement regulators 
C1inh and fH were significantly raised in patients with MS 
compared with controls, with no difference seen in plasma 
levels of clusterin or factor I (Table 4, Figure 1). A logistic 
regression model examining patients with MS and normal 
healthy controls was constructed using variables showing a 
significant difference on t-test and limited to analysis of C9 
(OR 0.87; 95% CI 0.80–0.93, p<0.001), C3 (OR 1.00; 
95%CI 1.00–1.01, p=0.035), C1inh (OR 1.03; 95% CI 
1.01–1.05, p=0.002) and fH (OR 1.01; 95% CI 1.00–1.02, 
p=0.077). C4 (OR 1.01; 95% CI 0.99–1.02, p=0.520) was 
excluded from the model (the significance of change if 
removed p=0.518). A ROC curve was established based on 
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the probabilities of the predicted values in the model and 
the C statistic based on this model was 0.97 (95% CI 0.93–
1.00, p<0.001) and superior to any individual component 
(C9 0.14, 95% CI 0.07–0.22; C3 0.67, 95% CI 0.56–0.77; 
C1inh 0.83, 95% CI 0.76–0.90; fH 0.76, 95% CI 0.67–
0.85) (Figure 2).
Dynamic changes in plasma complement 
levels in acute relapse
Analysis of disease course subgroups demonstrated ele-
vated mean levels of complement components C9 
(p=0.102) and fB (p=0.174) (Table 2), activation product 
C4a (p=0.011) (Table 3) and regulator fH (p=0.719) (Table 
4) in A-RRMS compared with S-RRMS. A logistic regres-
sion model was developed to assess A-RRMS compared 
with S-RRMS; an initial model using fB, C9, C4a and fH 
along with objective clinical features age, gender and dis-
ease duration; revealed no contribution to the model from 
fB (the significance of change if fB was removed from the 
model = 0.446), gender (0.280), C4a (0.414) or fH (0.191). 
The optimal model used C9 (OR 1.04, 95% CI 1.01–1.07, 
p=0.023), age (OR 0.88, 95% CI 0.82–0.95, p=0.001) and 
disease duration (OR 1.12, 95% CI 1.03–1.22, p=0.009). 
The C statistic based on the area under the ROC curve for 
this model to predict A-RRMS from S-RRMS was 0.73, 
95% CI 0.63–0.83 (Figure 3).
Where higher mean plasma analyte levels were seen in 
A-RRMS, an extended analysis was conducted with 
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Figure 1. Plasma levels of C3, C4, fH and C1 inhibitor were 
increased and plasma levels of C9 were decreased in MS patients 
compared with normal controls.
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measurement of convalescent samples post relapse at 2–3 
and 5–7 months. There were no differences in mean plasma 
levels between acute relapse and convalescent samples for 
either C9 or fB (Table 5). Mean plasma fH levels were sig-
nificantly higher in A-RRMS compared with both 2–3 
(p=0.013) and 5–7 (p=0.007) month convalescent samples 
(Table 5, Figure 4); levels were reduced in 26 of 44 subjects 
at 2 months and 30 of 44 subjects at 6 months, suggesting 
inter-individual variability in the convalescent response. 
Use of steroids post relapse did not alter the plasma com-
plement concentrations (Supplemental Table 1). Changes 
in C4a post relapse have been reported previously.16
Analysis of phenotypic parameters showed no correla-
tion of any measured components with gender, disease 
duration, EDSS, Multiple Sclerosis Severity Score or time 
to secondary progressive disease from onset. There was 
weak correlation of both plasma C9 (r=0.16) and C1s 
(r=0.12) with age; however, using age as a covariate in our 
previous analysis did not alter results (data not shown). 
There was no difference in levels of CRP between the total 
MS population (mean CRP 2.82, SD 3.98, n=82) and the 
control group (mean 2.76, SD 6.48, n=35), or between MS 
disease subgroups (S-RRMS mean 3.14, SD 4.37, n=20; 
A-RRMS mean 2.65, SD 3.82, n=20; SPMS mean 2.48, SD 
3.87, n=22; PPMS mean 3.04, SD 4.11, n=20), demonstrat-
ing the lack of acute phase response at times of complement 
upregulation.
Changes in complement levels in the CSF
It was possible to measure complement components fB, 
C9, C1s, clusterin, fI and TCC in CSF using the assays 
described (levels of fH and C4a in CSF have been described 
previously);15,16demographic details of patients and con-
trols are shown in Table 6. Levels of fB and C9 in both CSF 
and plasma were reduced in patients with MS and CIS com-
pared with the control population; however, this only 
reached significance in plasma C9 levels (Table 7). C9 
CSF/plasma ratio and C9 index were also non-significantly 
reduced in MS patients compared with controls (Table 7). 
Levels of CSF and plasma C1s, clusterin and TCC were 
increased in patients with MS and CIS compared with con-
trols; this only reached significance for plasma clusterin in 
CIS cases; given the sample size, this finding may be the 
result of a type 1 error. There were no changes seen in CSF 
or plasma fI.
In order to examine the relationship between levels of 
complement proteins in CSF and blood–CSF barrier (BCB) 
integrity, correlation of CSF:plasma complement concen-
trations with the CSF:serum albumin ratio was assessed21,22 
(Table 8). Both fB (r=0.38; p=0.004) and C9 (r=0.65; 
p<0.001) correlated with CSF:serum albumin ratio, sug-
gesting that intrathecal consumption was partially compen-
sated by leakage across the BCB. CSF C1s (r=0.35; 
p=0.011) and clusterin (r=0.36; p=0.007) also correlated 
with CSF:serum albumin ratio, demonstrating effects of 
BCB leak; indeed, levels of C9, C1s and clusterin were all 
significantly higher in patients with elevated CSF:serum 
albumin ratios compared with those with values in the nor-
mal range (Table 8). The relationship of CSF complement 
protein levels with IgG index, a measure of intrathecal IgG 
synthesis and a suggested measure of disease activity,23 was 
also tested. Levels of fB (r=0.41; p=0.001) and C9 (r=0.46; 
p<0.001) showed moderate correlation but none of the 
other parameters did; levels of fB and C9 were significantly 
higher in patients with elevated IgG index compared with 
those with values in the normal range (Table 8), implying a 
relationship with disease activity. Levels of CSF fI and 
TCC showed no correlation with either CSF:serum albu-
min ratio or IgG index.
Examination of disease characteristics showed weak to 
moderate correlation of CSF fB, C9, C1s and clusterin with 
age (fB r= 0.23, p=0.068; C9 r=0.39, p=0.002; C1s r=0.23, 
p=0.079; clusterin r=0.38, p=0.002); however, no correlation 
was seen with disease duration. CSF C9 showed a weak cor-
relation with disability measured by EDSS (r=0.33, p=0.03).
Table 3. Complement activation products in multiple sclerosis disease subgroups and controls.
Bb mg/l       C4a mg/l  p  p*
 No. Mean SD No. Mean SD
Control 35 1.04 0.21 35 819.65 570.94 N/A <0.001
Total MS 82 1.07 0.30 176 1477.27 941.15 <0.001 N/A
S-RRMS 20 1.03 0.32 37 1180.66 784.56 1.000 0.011
A-RRMS 20 0.98 0.19 68 1692.26 1080.47 <0.001 N/A
SPMS 22 1.14 0.31 34 1288.56 736.92 0.316 0.190
PPMS 20 1.31 0.42 37 1579.80 646.69 0.154 1.000
SD, standard deviation p-values are measured using students t-test to compare MS and controls and ANOVA for multiple comparisons. p-values are 
shown for the subgroup analysis if a significant difference was seen at ANOVA. p = comparison with control group. p* = comparison with A-RRMS 
group. S-RRMS, stable relapsing–remitting MS with no relapses reported for at least 12 months; A-RRMS, acute relapsing–remitting MS sampled in 
relapse; SPMS, secondary progressive MS; PPMS, primary progressive MS.
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Discussion
Although MS is a predominantly T-cell mediated disease, it 
is well established that complement plays an important 
role. We have previously demonstrated both systemic and 
local concentration changes for complement regulator fH15 
and generation of the activation fragment, C4a.16 Here, 
analysis of local and systemic complement components and 
activation fragments in MS patients is extended with the 
aim of clarifying the contribution of complement to disease 
Figure 2. Receiver operated characteristic (ROC) curve to 
predict the probability of MS compared to control subjects.
Combined model C statistic 0.97. For the individual components of the 
model; C3 C statistic 0.67, C9 C statistic 0.14, C1inh C statistic 0.83 and 
fH C statistic 0.76.
Figure 3. ROC curve to predict the probability of A-RRMS 
from S-RRMS.
Combined model C statistic 0.73. For the individual components of the 
model; C9 C statistic 0.63, disease duration C statistic 0.53 and age C 
statistic 0.34.
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processes, and combined complement profiles and pheno-
type models are examined to identify biomarkers of disease 
and disease course.
Given the complex and variable immunopathogenesis of 
MS, the use of combinations of plasma analytes to develop 
informative biomarkers of disease and disease course is 
likely to be more instructive than using isolated measure-
ment. The model developed here for distinguishing MS 
from controls used a combination of plasma complement 
components C3, C4, C9 and regulators fH and C1inh to 
give a predictive probability of 97%. The use of this model 
in the clinical setting is limited in its current form in terms 
of distinguishing MS from other confounding diagnoses or 
CIS; however, analysis using additional and larger patient 
subgroups and clinically relevant control groups may clar-
ify this. Additional complement profiles to distinguish dis-
ease subgroups were not established. No measured 
component other than fH was specific for disease progres-
sion, and although C9, C4a and fH all showed differential 
changes in relapse, when combined, they did not produce a 
reliable predictive model. This may have been because of 
innacuracies in the clinical classification of relapse and 
progression, or it may be that other complement proteins or 
inflammatory markers would be more useful in establishing 
biomarker profiles. However, the addition of complement 
measurements to objective clinical characteristics, disease 
duration and age, to distinguish disease state was of value, 
with a combined model predictive probability for relapse of 
73%. We have therefore established the potential use of 
complement profiles as plasma biomarkers for disease, 
although there is a need for this work to be replicated by 
independent groups to confirm utility of these models in 
clinical practice, which would be best achieved in an inde-
pendent prospective cohort with parallel MR data.
Systemic and local consumption of complement com-
ponents was demonstrated throughout MS disease course, 
with reduced levels of both plasma fB and plasma and CSF 
C9 in the total MS population and increased systemic pro-
duction in acute relapse. This was associated with raised 
plasma C3 and C4 levels in MS in the absence of any other 
evidence of an acute phase reponse, demonstrated by nor-
mal levels of CRP. We have previously demonstrated 
raised levels of C4a, an activation fragment of C4, isolated 
to acute relapse, and raised CSF C4a in the total MS 
Table 5. Serum factor H, factor B and C9 post relapse.
Months post 
relapse
No. Factor H mg/l Factor B mg/l C9 mg/l
 Mean SD p Mean SD p Mean SD p
0 44 205.72 63.80 N/A 247.50 86.18 N/A 96.95 31.47 N/A
2-3 44 178.81 42.93 0.013 270.69 70.05 0.158 99.79 29.54 0.678
5-7 44 176.39 39.28 0.007 243.62 71.52 0.813 97.88 32.14 0.891
FH, Factor H; FB, Factor B; SD, standard deviation. p = p-value for comparison with acute relapse (month 0).
Figure 4. Plasma factor H levels post relapse.
A reduction in plasma factor H is seen post relapse in 26 of 44 patients 
at 2-3 months and 30 of 44 patients at 5-7 months. Mean levels are 
significantly reduced at both time points (p=0.013 at 2–3 months and 
p=0.007 at 5–7 months).
Table 6. Demographic details and routine cerebrospinal fluid results.
No.    Age Gender Disease duration        EDSS  Albumin ratio     Ig index  OCB
 Mean SD %f Mean SD Mean SD Mean SD Mean SD % +ve
Control 24 49.79 13.52 79.17 N/A N/A N/A N/A 5.24 2.79 0.50 0.05 0.00
MS 37 38.81 10.76 75.68 7.11 8.57 2.55 2.10 5.33 1.93 1.00 0.48 91.89
CIS  5 40.00  9.35 100.00 0.80 0.45 2.00 1.58 6.14 2.31 0.79 0.44 40.00
EDSS, Expanded Disability Status Scale; Albumin ratio, CSF albumin mg/l / serum albumin g/l; Ig Index, derived from cerebrospinal fluid /plasma ratios 
of IgG and albumin concentrations; OCB, oligoclonal bands; SD, standard deviation; CIS, clinically isolated syndrome.
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population examined.16 These results imply continuous 
activation of complement with dynamic effects that are 
both local and systemic. The observed changes in comple-
ment regulators fH and C1inh are in concordance with this 
suggestion.
Two previous studies found no significant change in 
plasma C9 in MS patients;12,24 however, these studies were 
limited in terms of patient numbers and underpowered to 
detect change. Local reduction of C9 levels shown here is 
consistent with previous studies;12,24 however, given the 
nature of our CSF control group, containing patients with 
other neurological and inflammatory conditions, there may 
have been more complement activation in the controls than 
would be seen in normal healthy controls, limiting the dif-
ference in C9 observed. Interestingly, CSF C9 in our study 
did show some degree of correlation with disability, previ-
ously only shown in CSF TCC measurements in a single 
study.13 Further work with extended analysis of CSF C9 
and/or TCC in MS disease subgroups and patients with CIS 
may be useful in determining whether these changes in ter-
minal pathway components and activation products corre-
lating with disability could be clinically informative.
In vitro studies have established not only that CNS cells 
produce all complement components necessary for comple-
ment lysis,25–27 but also that complement is a tissue-damag-
ing factor in demyelination and neurodegeneration.28–30 
However, it is still unclear how this relates to in vivo 
pathology, and whether complement proteins seen in MS 
white matter plaques are locally produced or are a result of 
BCB breakdown. This study demonstrates that the majority 
of complement proteins, including C9, C1s, fB, fH and 
clusterin, leak into the CSF at times of BCB breakdown, as 
well as suggesting local biosynthesis of selected compo-
nents including fB and C9. Evidence from this study there-
fore suggests that both locally and systemically synthesised 
complement contributes to the disease process in MS. 
Given that the vast majority of complement synthesis is 
hepatic, it is possible that systemically targeted anti- 
complement therapies may significantly reduce the extent 
of local complement attack within the CNS and be of use in 
patients with MS in addition to more traditional adaptive 
immune-targeted therapies.
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